microdosing glp 1 perimenopause What Is GLP-1 Microdosing? How Lower Doses of Semaglutide and Tirzepatide Work Microdosing GLP-1 in Perimenopause &

PMID: 37385280.

Coverage expansion is expected to continue through 2025, particularly within Medicaid programs and employer-sponsored health plans

Their potent effects on weight, appetite, and metabolism require medical supervision to ensure safety and proper dosing. Unmonitored or over-the-counter use can lead to serious risks, including gastrointestinal complications, pancreatitis, or thyroid-related issues

Is Coverage Expanding on April 1, 2026

Chiang CH, Jaroenlapnopparat A, Colak SC, et al

The analysis of BMI subgroups showed HRs of 0.87 (95% CI: 0.830.91) for BMI 2530 kg/m 2 and 0.86 (95% CI: 0.810.90) for BMI 30 kg/m 2